Cargando…

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

SIMPLE SUMMARY: PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) are widely used in metastatic melanoma, and most immune-related adverse events are known. Recently, several cardiovascular AEs (CVAEs, i.e., myocardial infarction, heart failure, stroke, Takotsubo syndrom...

Descripción completa

Detalles Bibliográficos
Autores principales:	L’Orphelin, Jean-Matthieu, Dollalille, Charles, Akroun, Julia, Alexandre, Joachim, Dompmartin, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093552/ https://www.ncbi.nlm.nih.gov/pubmed/37046831 http://dx.doi.org/10.3390/cancers15072170

Ejemplares similares

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2021)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023)

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
por: Bailly-Caillé, Barbara, et al.
Publicado: (2023)

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
por: Jouandet, Marie, et al.
Publicado: (2022)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

In vivo assessment of immunotoxicity
por: Munson, Albert E., et al.
Publicado: (1982)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements
por: Giannakou, Christina, et al.
Publicado: (2016)

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
por: van de Donk, Pim P., et al.
Publicado: (2021)

Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report
por: Langan, Ewan A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hllij6qqpi17kknject9d9skj